Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma

摘要: BACKGROUND In the era of highly active antiretroviral therapy (HAART), standard-dose chemotherapy for human immunodeficiency virus (HIV)-associated diffuse large B-cell lymphoma is becoming standard care. In contrast, safety and efficacy intensive regimens have not been established Burkitt (BL), a aggressive which moderate-dose substandard in HIV-negative population. METHODS To evaluate feasibility HIV-associated BL, authors retrospectively reviewed 14 HIV-positive adults with BL treated at their center between 1988 2000. Eight patients were 1996 2000 cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, cytarabine (CODOX-M/IVAC), one currently preferred intensive-dose BL. Six received other chemotherapy. Outcomes compared those 24 adult who had similar patient characteristics concomitantly (13 CODOX-M/IVAC; 11 regimens). RESULTS Of patients, 63% complete response after CODOX-M/IVAC treatment, 67% receiving The 2-year event-free survival (EFS) rates 60% or regimens, respectively. Similar outcomes seen despite fact that 88% CODOX-M/IVAC-treated Stage IV disease, one-third HIV status did adversely affect long-term EFS independent treatment regimen (P = 0.88). When was evaluated according to status, found be associated improved 0.05) all particularly high risk. tolerated well myelosuppression infectious complications as patients. CONCLUSIONS The current nonrandomized retrospective study suggested feasible post-HAART era, such may appropriate especially poor prognostic factors, regardless status. Cancer 2003;98:1196–205. © 2003 American Society. DOI 10.1002/cncr.11628